Incyte Corporation Equity-NMS: INCY

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$70.39
Open :	$70.43
Today's high :	$72
Today's low :	$70.33
52W low :	$50.3498
52W high :	$83.95
1Y :	31.98%
5Y :	-24.43%
EPS(TTM): :	0.09
Shares O/S :	192.65 M
Market cap :	13.85 B

What is the share price of Incyte Corporation today?

Incyte Corporation (INCY) share price as of November 21, 2024, is $70.39. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Incyte Corporation?

Yes, Indian Investors can invest in the Incyte Corporation (INCY) Share by opening an international trading account with Angel One.

How can I purchase Incyte Corporation shares in India?

Purchasing Incyte Corporation (INCY) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Incyte Corporation (INCY) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Incyte Corporation?

Yes, you can purchase fractional shares of Incyte Corporation (INCY) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Incyte Corporation?

The market capitalization of Incyte Corporation on November 21, 2024, is $13.83 B.

In which sector Incyte Corporation belongs?

Incyte Corporation operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Incyte Corporation stocks?

In order to invest in Incyte Corporation (INCY) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.